Artios Pharma
UK - CambridgePharmaceutical
Focus: Artios Pharma is a newly public UK-based oncology biotech focused on DNA Damage Response (DDR) therapies for advanced cancers. The company operates at an early clinical stage with a pipeline of four programs spanning Phase 1 to Phase 2 development.
Profile data last refreshed 19h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Artios Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Artios Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Artios Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Determination of ATM alteration status.
Solid Tumor, Unspecified, AdultClinical Trials (1)
NCT04976803Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
N/AHelp build intelligence for Artios Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.